Vistagen's Fasedienol Shows Positive Preliminary Safety, Efficacy in Phase 3 Social Anxiety Trial
VTGN sits 44% above its 52-week low of $0.43.
Summary
Vistagen Therapeutics announced preliminary positive safety and exploratory efficacy data from the ongoing open-label extension portion of its PALISADE-3 Phase 3 study for fasedienol nasal spray, targeting the acute treatment of social anxiety disorder. The data indicated fasedienol was well-tolerated with no new safety findings after 12 months and no serious adverse events reported. This positive update on a key pipeline asset is significant for the company, especially given its recent "going concern" warning, providing crucial safety reassurance and early efficacy signals. Investors will now closely watch for the topline data from the PALISADE-4 study, which is expected in Q2 2026, for definitive efficacy results.
At the time of this announcement, VTGN was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.7M. The 52-week trading range was $0.43 to $5.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.